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Cardiovascular risk in patients with mild renal insufficiency: People with end-stage renal disease (ESRD) die from
Implications for the use of ACE inhibitors. We reviewed the cardiovascular disease at a much younger age than peo-
evidence linking mild renal insufficiency (MRI) to an increased
ple in the general population [1, 2]. Age-adjusted cardio-cardiovascular risk. A number of cardiovascular risk factors
vascular mortality is about 30 times higher in ESRD thanbecome prevalent with MRI, including night-time hyperten-
sion, increase in lipoprotein(a), in homocysteine, in asymmetric in the general population [1, 3]. The increase in CV risk
dimethyl-arginine (ADMA), markers and mediators of in- associated with ESRD may be due to several mecha-
flammation, and insulin resistance. Also, an epidemiologic as-
nisms, including hemodynamic overload due to hyper-sociation between coronary artery disease and nephrosclerosis,
tension and anemia, dyslipidemia, a high prevalence ofa frequent cause of mild renal insufficiency in the elderly,
is documented. In the middle-aged, general population MRI, diabetes and impaired glucose tolerance, prothrombotic
found in 8% of women and 9% of men, was not associated with changes, hyperhomocysteinemia, increased oxidant stress,cardiovascular disease. However, in a representative sample of
neurohormonal overactivity, divalent ion abnormalities,middle-aged British men, the risk of stroke was 60% higher
for the subgroup of people with MRI; in people at high cardio- and inflammation [1]. Whereas some of these factors
vascular risk (mostly coronary disease), the HOPE study found have been shown to predict the risk of future cardiovas-
a 2-fold (unadjusted), or 1.4-fold (adjusted), higher incidence of cular events in chronic renal disease [1], studies withincardiovascular outcomes with MRI. The incidence of primary
an intervention trial that include hard end points areoutcome increased with the level of serum creatinine. Several
studies determined the cardiovascular risk associated with MRI lacking, apart from a trial investigating the normalization
in hypertension. In HDFP, as in HOPE, cardiovascular mortal- of hemoglobin levels [3] and a trial with administration
ity increased with higher serum creatinine (five-fold difference
of vitamin E [4].in cardiovascular mortality between the lowest and the highest
Only recent research was looking into the questioncreatinine strata). The risk associated with renal insufficiency
was independent from other classic cardiovascular risk factors. whether mild renal insufficiency is also associated with
In hypertensives with low risk, the HOT, and a small Italian an increased cardiovascular risk. Some of the above
trial found about a doubling in cardiovascular outcomes in
listed pro-atherogenic factors are present in early or mildMRI. However, in MRFIT, increase in follow-up creatinine
renal insufficiency. Ritz et al [5] demonstrated a rise inpredicted future cardiovascular disease, not baseline creatinine.
These observational data suggest that MRI, independent of blood pressure within the normotensive range, especially
etiology, is a strong predictor of cardiovascular disease, present night-time blood pressure, and cardiac remodeling atin 10% of a population at low risk, and up to 30% at high
very early stages of renal disease [5]. Lipoprotein(a)cardiovascular risk. No prospective therapeutic trials, aimed
at reducing the cardiovascular burden in people with MRI, are [6], inhibitors of NO formation like ADMA (Fliser and
available. Subgroup analyses of the HOPE study indicate that Haller, personal communication) and homocysteine se-
ACE inhibition with ramipril is beneficial without an increased rum concentrations [7], also increase at initial stages ofrisk for side effects like acute renal failure or hyperkalemia.
renal disease, as does insulin resistance [8]. In additionThus, the frequent practice of withholding ACE inhibitors from
patients with mild renal insufficiency is unwarranted, especially to those mechanisms, an epidemiologic association be-
since this identifies a group at high risk that appears to benefit tween coronary artery disease and nephrosclerosis, a
most from treatment. In addition, there is evidence that ACE
frequent cause of early renal insufficiency in the elderly,inhibitors improve renal outcomes in renal insufficiency. Pro-
has been noted [9, 10].spective studies should test the predictive power of MRI for
cardiovascular disease and therapeutic options. Here, we will review the evidence linking early or mild
renal insufficiency, defined as serum-creatinine above
normal to 250 uM, to cardiovascular risk in several popu-
Key words: serum creatinine, urine albumin, blood pressure, myocar-
lations. No doubt, such serum-creatinine levels may indi-dial infarction, mortality, stroke, cardiovascular, death, ramipril, micro-
albuminuria, renal insufficiency. cate more than mild renal insufficiency, especially in frail
elderly people. 2003 by the International Society of Nephrology
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MILD RENAL INSUFFICIENCY: AN INDICATOR predicts cardiovascular disease in the general population.
However, early renal insufficiency detects only a rela-PREDICTOR OF AN INCREASED
tively small portion of those with cardiovascular eventsCARDIOVASCULAR RISK IN THE
in the general population. How are those relationshipsGENERAL POPULATION
in cohorts at higher risk?The first longitudinal study that assessed early renal
insufficiency as a predictor of future cardiovascular risk
in the general population was the Framingham Heart MILD RENAL INSUFFICIENCY AND
Study [12]. Approximately 6200 subjects with a mean CARDIOVASCULAR RISK IN PEOPLE WITH
age of 54 were followed from the first measurement of ATHEROSCLEROTIC VASCULAR DISEASE
serum-creatinine from 1977 to 1983, until 1994. At the The hypothesis that early renal insufficiency is an inde-
time of first serum-creatinine measurement, only 15% pendent predictor of cardiovascular outcomes in people
of the individuals had evidence of cardiovascular disease. with cardiovascular disease was tested using data from
Early renal insufficiency, defined as a serum-creatinine the HOPE study [14]. This trial investigated the effects of
of 1.4 to 3.0 mg/dL, was found in 8% of women and 9% inhibition of the renin-angiotensin system with ramipril,
of men at baseline. During 15 years of follow up, early and of antioxidant therapy with vitamin E on myocardial
renal insufficiency at baseline was associated with a sig- infarction, cardiovascular death, or stroke in 9297 pa-
nificant increase in age- and multivariate-adjusted all- tients at high risk for cardiovascular events, including
cause mortality in men, but not with cardiovascular dis- subjects with serum-creatinine 2.3 mg/dL (200 M).
ease. However, there was a trend for such association. We compared outcomes in people with a serum-creati-
The Framingham data are based on a substantial number nine of 1.4 to 2.3 mg/dL (N  980) to those with lower
of end points, including1000 cardiovascular events and levels of serum-creatinine (N  8307). Similar compari-
1406 deaths; only 516 people exhibited renal insuffi- sons were done after dividing the population according
ciency, a relatively small cohort. Thus, the cardiovascular to a calculated Ccrea of 65 mL/min (N  3394) and
risk estimates in those with renal dysfunction are not 65 mL/min (N  5888). In other words, in this cohort
reliable. of patients from cardiology and diabetology clinics, and
In another study, a representative sample of 7690 mid- excluding patients with a serum-creatinine 2.3mg/mL
and with clinical albuminuria, a third had impaired renaldle-aged British men were followed for 15 years; at base-
function!line, 75% had no evidence of cardiac disease and 5%
The cumulative incidence of the composite primaryhad a history of myocardial infarction [13]. In a post-
outcome was significantly higher in patients with renalhoc analysis, the risk of stroke was 60% higher for the
insufficiency (22.2% vs. 15.1% or 55 vs. 36 events persubgroup of people with a serum-creatinine value 1.3
1000 patient years) (Fig. 1). Moreover, the incidencemg/dL (N  343) than for people with lower values,
of primary outcome increased with the level of serumeven after adjustment for several other cardiovascular
creatinine (Fig. 2). The effect of renal insufficiency, basedrisk factors.
on serum-creatinine 1.4 mg/dL or Ccrea 65 mL/min,Two further studies on representative samples of the
on the primary outcome (adjusted hazard ratio [HR]general population were published as abstracts (J Am
1.40; 95% CI: 1.16 to 1.69) was independent of knownSoc Nephrol 2001;12:225A). The ARIC study followed
cardiovascular risk factors and treatments.15,350 randomly selected people, aged 45 to 64 years
An association between renal and cardiovascular dis-for six years; 965 cardiovascular events occurred. The
ease has been clearly established for people with diabetesadjusted cardiovascular hazard ratio for those with a
mellitus and for those with hypertension. We thereforecreatinine clearance (Ccrea) 60 mL/min was 1.38 (1.02
analyzed nondiabetic and normotensive subjects sepa-to 1.87) as compared to people with a Ccrea 90. In
rately (Fig. 3). The impact of early renal insufficiencythe Cardiovascular health study, 5808 randomly selected
on primary and secondary outcomes in HOPE was notelderly people (65 years) were followed over seven
affected by the presence of either diabetes or hyperten-years. Mild renal insufficiency, present in 11%, was asso-
sion. It was also not affected by albuminuria—anotherciated with a doubling of total mortality, cardiovascular
substantial renal-related cardiovascular risk predictor [15].
death, stroke, and heart failure. Interestingly, the latter
two studies in the general middle-aged and elderly popu-
MILD RENAL INSUFFICIENCY ANDlation provide risk estimates for total mortality and for
CARDIOVASCULAR RISK IN PEOPLE WITHcardiovascular disease, as associated with mild renal in-
HEART FAILURE AND WITH ACUTEsufficiency, that are almost overlapping with recent data
CORONARY SYNDROMESfrom the HOPE study (see below) that included people
with known atherosclerotic vascular disease [14]. In a thorough study of stable patients with severe
heart failure (NYHA class III and IV) Hillege et al [25]The above data suggests that early renal insufficiency
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Fig. 1. Bar graph showing the main outcomes
of the HOPE study. Primary outcome (A),
myocardial infarction (MI) (B), cardiovascu-
lar death (C ), and total mortality (D) for
groups with a serum creatinine concentration
1.4 mg/dL and 1.4 are shown. All patients
and patients on either ramipril or placebo are
given. Data are given as events per 1000 pa-
tient years.
sively super-imposable and close to the risk estimates of
the HOPE study [14]. Also, in people cared for in a coro-
nary care unit, reduced GFR predicted poor outcome [11].
MILD RENAL INSUFFICIENCY AND
CARDIOVASCULAR RISK IN PEOPLE
WITH HYPERTENSION
At least four studies determined the cardiovascular
risk associated with early renal insufficiency in people
with hypertension [16–19]. Data derived from 10,940 pa-Fig. 2. Bar graph showing the frequency of the primary outcome of the
tients from the Hypertension Detection and Follow-upHOPE study according to quartiles of serum creatinine concentration
(quartiles: 0.93; 0.93 to 1.08; 1.09 to 1.22; 1.23 mg/dL). Frequencies Program (HDFP) [16] are consistent with the findings
are given for all patients. There was a significant increase in risk with of the HOPE study. The HDFP study did include pa-increasing serum creatinine concentration (P  0.0001 for trend, risk
tients with known renal diseases (i.e., those with serumratio 2.34 for a 1 mg/dL increase in serum creatinine from one quartile
to the next). creatinine above 1.5 mg/dL (5.8%) and those with 2
proteinuria (3.1%). The presence of hypertension in all
subjects, and inclusion of some subjects with 2 pro-
teinuria, in HDFP are to be noted. As in HOPE, a linearanalyzed a large variety of hemodynamic and serologic
relation was found in HDFP between serum creatininerisk markers. When those patients were followed long
concentration and cardiovascular mortality over the five-term, impaired renal function surprisingly turned out to
year follow-up, with a five-fold difference in cardiovascu-be the best predictor of mortality. The same authors
lar mortality between the lowest and the highest creati-recently reported that the development of heart failure
nine strata [16]. The Hypertension Optimal Treatmentitself after acute myocardial infarction (excluding unsta-
(HOT) study [17] followed 18,790 people with hyperten-ble patients like those with cardiogenic shock, etc.) is
sion for four years and assigned them to three diastolicpredicted by low GFR [26]. Hillege et al excluded people
blood pressure target groups. Most participants (aboutwith a serum-creatinine180 mol/L. A third of the trial
90%) did not have evidence of atherosclerotic vascularparticipants had a GFR 80 mL/min. Reduced GFR
disease. A baseline serum-creatinine value3 mg/dL waswas the only independent predictor of congestive heart
an exclusion criterion and proteinuria was not analyzed.failure, apart from the wall motion score index. The
There was a significant two-fold increase in adjustedsingle center data of Hillege et al are supported by a
relative risk for major cardiovascular outcomes, and forlarge post-hoc analysis of several of 10,000 participants
all-cause mortality, in people with a baseline serum-cre-in recent acute coronary syndrome intervention studies
atinine1.5 mg/dL (45 events in 470 people as compared[27]. In each trial, with or without ST-segment elevation
to 626 events in 18,127 people, or 10% vs. 3.5%).in the ECG, the presence of mild renal insufficiency at
The above data in hypertensive populations were con-baseline was highly predictive of short-term survival. The
adjusted hazard ratios of the various trials were impres- firmed by a smaller observational study in Italy [18].
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Fig. 3. Bar graph showing the frequency of
the primary outcome of the HOPE study in
patients with a serum-creatinine1.4 and1.4
mg/dL, divided into subgroups with and with-
out diabetes mellitus (A) and with and without
hypertension (B).
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